| Drug Name: | Neomycin (1404-04-2) |
|---|---|
| PubChem ID: | 24978553 |
| SMILES: | C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O |
| InchiKey: | KWBUARAINLGYMG-JGMIRXPNSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Enzyme Inhibitors, Protein Synthesis Inhibitors |
| Molecular Weight (dalton) | : | 908.887 |
| LogP | : | -10.8537 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 25 |
| Hydrogen Bond Donor Count | : | 19 |
| Total Polar Surface Area | : | 576.91 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cell Loss And Degeneration | Glial fibrillary acidic protein (P14136) | Neomycin treatment also INCREASED GFAP and OX-6 immunostaining@ as well as cell loss and degeneration in the lesioned area@while a higher dose of neomycin (50 nmol) causing more DRAMATIC cell loss and degeneration with extensive striatal GFAP and OX-6 immunoreactivity [ ADR Type 5 ] | Aminoglycoside neurotoxicity involves NMDA receptor activation |
| Cell Loss And Degeneration | MHC class II antigen OX-6 (P00033) | Neomycin treatment also INCREASED GFAP and OX-6 immunostaining, as well as cell loss and degeneration in the lesioned area,while a higher dose of neomycin (50 nmol) causing more DRAMATIC cell loss and degeneration with extensive striatal GFAP and OX-6. immunoreactivity. [ ADR Type 5 ] | Aminoglycoside neurotoxicity involves NMDA receptor activation |
| Excitotoxic Activation | NMDA receptor-regulated protein (Q9BXJ9) | Ototoxicity produced by neomycin involves the excitotoxic activation of cochlear NMDA receptors. [ ADR Type 2 ] | Aminoglycoside neurotoxicity involves NMDA receptor activation |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category